Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy (original) (raw)

• Alemany, R., Balague, C. & Curiel, D.T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18, 723–727 (2000).
  Article CAS PubMed Google Scholar
• Kirn, D.H. & McCormick, F. Replicating viruses as selective cancer therapeutics. Mol. Med. Today. 2, 519–527 (1996).
  Article CAS PubMed Google Scholar
• Kirn, D., Martuza, R.L. & Zwiebel, J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 7, 781–787 (2001).
  Article CAS PubMed Google Scholar
• Yu, D.C., Sakamoto, G.T. & Henderson, D.R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59, 1498–1504 (1999).
  CAS PubMed Google Scholar
• Hallenbeck, P.L. et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10, 1721–1733 (1999).
  Article CAS PubMed Google Scholar
• Favrot, M., Coll, J.L., Louis, N. & Negoescu, A. Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Ther. 5, 728–739 (1998).
  Article CAS PubMed Google Scholar
• Lin, X., Denmeade, S.R. & Isaacs, J.T. The genetics of programmed (apoptotic) cell death. Cancer Surv. 25, 173–194 (1995).
  CAS PubMed Google Scholar
• Bischoff, J.R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373–376 (1996).
  Article CAS PubMed Google Scholar
• Rancourt, C. et al. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy. Clin. Cancer Res. 5, 43–50 (1999).
  CAS PubMed Google Scholar
• Fueyo, J. et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2–12 (2000).
  Article CAS PubMed Google Scholar
• Doronin, K. et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147–6155 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Howe, J. et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol. Therapy 2, 485–495 (2000).
  Article CAS Google Scholar
• Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134–1139 (2000).
  Article CAS PubMed Google Scholar
• Harada, J.N. & Berk, A.J. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73, 5333–5344 (1999).
  CAS PubMed PubMed Central Google Scholar
• Heise, C. et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639–645 (1997).
  Article CAS PubMed Google Scholar
• Heise, C.C., Williams, A.M., Xue, S., Propst, M. & Kirn, D.H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59, 2623–2628 (1999).
  CAS PubMed Google Scholar
• Yu, D.C., Chen, Y., Seng, M., Dilley, J. & Henderson, D.R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59, 4200–4203 (1999).
  CAS PubMed Google Scholar
• Rogulski, K.R. et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60, 1193–1196 (2000).
  CAS PubMed Google Scholar
• Ganly, I. et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798–806 (2000).
  CAS PubMed Google Scholar
• Khuri, F.R. et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879–885 (2000).
  Article CAS PubMed Google Scholar
• Kirn, D. et al. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol. 17, 391a (1998).
  Google Scholar
• Nemunaitis, J. et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289–298 (2001).
  Article CAS PubMed Google Scholar
• Sherr, C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60, 3689–3695 (2000).
  CAS PubMed Google Scholar
• Prives, C. & Hall, P.A. The p53 pathway. J. Pathol. 187, 112–126 (1999).
  Article CAS PubMed Google Scholar
• Tollefson, A.E., Ryerse, J.S., Scaria, A., Hermiston, T.W. & Wold, W.S. The E3–11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 220, 152–162 (1996).
  Article CAS PubMed Google Scholar
• Sellers, W.R., Rodgers, J.W. & Kaelin, W.G. Jr. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc. Natl. Acad. Sci. USA 92, 11544–11548 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Wills, K.N. et al. Tissue-specific expression of an anti-proliferative hybrid transgene from the human smooth muscle α-actin promoter suppresses smooth muscle cell proliferation and neointima formation. Gene Ther. in press (2001).
• Somasundaram, K. & El-Deiry, W.S. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 14, 1047–1057 (1997).
  Article CAS PubMed Google Scholar
• Lill, N.L., Grossman, S.R., Ginsberg, D., DeCaprio, J. & Livingston, D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature 387, 823–827 (1997).
  Article CAS PubMed Google Scholar
• Howe, J.A., Mymryk, J.S., Egan, C., Branton, P.E. & Bayley, S.T. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc. Natl. Acad. Sci. USA 87, 5883–5887 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Tollefson, A.E. et al. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70, 2296–2306 (1996).
  CAS PubMed PubMed Central Google Scholar
• Parr, M.J. et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med. 3, 1145–1149 (1997).
  Article CAS PubMed Google Scholar
• Nemunaitis, J. et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359–6366 (2000).
  CAS PubMed Google Scholar
• Dix, B.R., Edwards, S.J. & Braithwaite, A.W. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J. Virol. 75, 5443–5447 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• McCormick, F. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin. Cancer Biol. 10, 453–459 (2000).
  Article CAS PubMed Google Scholar
• Ikeda, K. et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881–887 (1999).
  Article CAS PubMed Google Scholar
• Funk, W.D., Pak, D.T., Karas, R.H., Wright, W.E. & Shay, J.W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12, 2866–2871 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Jones, N. & Shenk, T. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc. Natl. Acad. Sci. USA 76, 3665–3669 (1979).
  Article CAS PubMed PubMed Central Google Scholar
• Thimmappaya, B., Weinberger, C., Schneider, R.J. & Shenk, T. Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 31, 543–551 (1982).
  Article CAS PubMed Google Scholar
• Barker, D.D. & Berk, A.J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107–121 (1987).
  Article CAS PubMed Google Scholar
• Wills, K.N. et al. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 2, 191–197 (1995).
  CAS PubMed Google Scholar
• Chartier, C. et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70, 4805–4810 (1996).
  CAS PubMed PubMed Central Google Scholar
• Huyghe, B.G. et al. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther. 6, 1403–1416 (1995).
  Article CAS PubMed Google Scholar
• Shabram, P.W. et al. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum. Gene Ther. 8, 453–465 (1997).
  Article CAS PubMed Google Scholar
• Wen, S.F. et al. Retinoblastoma protein monoclonal antibodies with novel characteristics. J. Immunol. Methods 169, 231–240 (1994).
  Article CAS PubMed Google Scholar
• Tollefson, A.E., Scaria, A., Saha, S.K. & Wold, W.S. The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J. Virol. 66, 3633–3642 (1992).
  CAS PubMed PubMed Central Google Scholar
• Musco, M.L. et al. Comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenoviral infectivity and p53 protein expression in gene therapy. Cytometry 33, 290–296 (1998).
  Article CAS PubMed Google Scholar